Artificial Intelligence (AI) is a potent, versatile technology helping to disrupt innovation across numerous fields. In the medical field, the success of AI has been well-publicised due to the ground-breaking innovations being made thanks to AI. Central to AI is machine learning (ML), which requires less pre-processing, is more rapid and can handle a variety of data formats, including numeric, text and images; compared to other modelling techniques. The project proposes to exploit the power of ML to develop a disruptive methodology toward formulation development in the pharmaceutical industry. The ultimate aim is to use ML for developing personalized medicine whilst achieving a more sustainable research in the process. If you are looking to perform research at the forefront of technology, develop highly transferrable skills and work with a multidisciplinary and multicultural team, then do consider applying to this opportunity.
Upon starting, the PhD candidate will join a renowned research group, supervised by Professor Abdul W. Basit, with expertise in formulation development, pharmaceutical 3D printing, and drug delivery. The project will be based at University College London (UCL), a top 10 University in the 2021 QS World Rankings, within the vibrant and welcoming School of Pharmacy. During their project, the PhD researcher will have access to gold-standard facilities and resources, with strong mentorship, support, and frequent career development opportunities.
The ideal candidate will have a background in pharmaceutics, engineering, or a similar degree. Previous experience in ML and coding is desirable but training will be provided.
Applications
Applications are welcome from both UK and overseas candidates. To apply, please send a CV and cover letter to Prof Abdul Basit at [Email Address Removed]. For more information on this project, please contact Prof Abdul Basit.
Continue with Facebook
